These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 9353181)

  • 1. Integrating genetic approaches into the discovery of anticancer drugs.
    Hartwell LH; Szankasi P; Roberts CJ; Murray AW; Friend SH
    Science; 1997 Nov; 278(5340):1064-8. PubMed ID: 9353181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desperately seeking genotype-selective anticancer agents.
    Lazo JS
    Chem Biol; 2003 Jun; 10(6):477-8. PubMed ID: 12837378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.
    Loni L; Del Tacca M; Danesi R
    Br J Cancer; 2001 Nov; 85(10):1425-31. PubMed ID: 11720423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer drug discovery in the future: an evolutionary perspective.
    Ma X; Wang Z
    Drug Discov Today; 2009 Dec; 14(23-24):1136-42. PubMed ID: 19800414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast as a model system for anticancer drug discovery.
    Simon JA; Bedalov A
    Nat Rev Cancer; 2004 Jun; 4(6):481-92. PubMed ID: 15170450
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging approaches in molecular profiling affecting oncology drug discovery.
    Friend SH
    Cold Spring Harb Symp Quant Biol; 2005; 70():445-8. PubMed ID: 16869782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing synthetic lethal interactions in anticancer drug discovery.
    Chan DA; Giaccia AJ
    Nat Rev Drug Discov; 2011 May; 10(5):351-64. PubMed ID: 21532565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Problems in the design of anticancer agents.
    D'Incalci M; Balconi G; Broggini M; Colombo T; Marzola M; Morali F; Pang Y; Sen S; Spinelli L
    Cancer Surv; 1989; 8(3):535-55. PubMed ID: 2701084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel molecular targets in cancer chemotherapy waiting for discovery.
    Kunick C
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):421-3. PubMed ID: 15379696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A lethal combination for cancer cells: synthetic lethality screenings for drug discovery.
    Ferrari E; Lucca C; Foiani M
    Eur J Cancer; 2010 Nov; 46(16):2889-95. PubMed ID: 20724143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
    Amoedo ND; Obre E; Rossignol R
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target selection issues in drug discovery and development.
    Sausville EA
    J Chemother; 2004 Nov; 16 Suppl 4():16-8. PubMed ID: 15688602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer Stem Cells (CSCs) as a Rational Therapeutic Cancer Target, and Screening for CSC-targeting Drugs].
    Mashima T
    Yakugaku Zasshi; 2017; 137(2):129-132. PubMed ID: 28154319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons Learned from Two Decades of Anticancer Drugs.
    Liu Z; Delavan B; Roberts R; Tong W
    Trends Pharmacol Sci; 2017 Oct; 38(10):852-872. PubMed ID: 28709554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yeast mutants as a model system for identification of determinants of chemosensitivity.
    Perego P; Jimenez GS; Gatti L; Howell SB; Zunino F
    Pharmacol Rev; 2000 Dec; 52(4):477-92. PubMed ID: 11121507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
    Kong D; Yamori T
    Bioorg Med Chem; 2012 Mar; 20(6):1947-51. PubMed ID: 22336246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of high-throughput, molecular-targeted screening to anticancer drug discovery.
    Shoemaker RH; Scudiero DA; Melillo G; Currens MJ; Monks AP; Rabow AA; Covell DG; Sausville EA
    Curr Top Med Chem; 2002 Mar; 2(3):229-46. PubMed ID: 11944818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.